1. Home
  2. Analysis
  3. Depakene
  4. Neoplasm-recurrence

Depakene and Neoplasm recurrence - a phase IV clinical study of FDA data

Summary:

Neoplasm recurrence is reported as a side effect among people who take Depakene (valproic acid), especially for people who are male, 50-59 old, have been taking the drug for 5 - 10 years also take Genotropin, and have Glioblastoma multiforme.

The phase IV clinical study analyzes which people have Neoplasm recurrence when taking Depakene. It is created by eHealthMe based on reports of 14,611 people who have side effects when taking Depakene from the FDA, and is updated regularly.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.

What is Neoplasm recurrence?

Neoplasm recurrence (reoccurrence of tumour) is found to be associated with 361 drugs and 495 conditions by eHealthMe. Check the latest studies of Neoplasm recurrence.

On Jul, 27, 2026

14,611 people reported to have side effects when taking Depakene.
Among them, 14 people (0.1%) have Neoplasm recurrence.

Could Depakene cause Neoplasm recurrence?

Among these 14 people:

How long have people been on Depakene when they have Neoplasm recurrence? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 100 %
  • 10+ years: 0.0 %

What is the gender of people who have Neoplasm recurrence when taking Depakene? *

  • female: 42.86 %
  • male: 57.14 %

What is the age of people who have Neoplasm recurrence when taking Depakene? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 30.77 %
  • 20-29: 0.0 %
  • 30-39: 7.69 %
  • 40-49: 15.38 %
  • 50-59: 38.46 %
  • 60+: 7.69 %

What are other drugs people take besides Depakene? *

  1. Cortril: 4 people, 28.57%
  2. Kytril: 4 people, 28.57%
  3. Decadron: 4 people, 28.57%
  4. Genotropin: 4 people, 28.57%
  5. Vepesid: 3 people, 21.43%
  6. Famotidine: 2 people, 14.29%
  7. Levothyroxine Sodium: 2 people, 14.29%
  8. Vioxx: 1 person, 7.14%
  9. Actos: 1 person, 7.14%
  10. Avandia: 1 person, 7.14%

What are other side effects people have besides Neoplasm recurrence? *

  1. Neoplasm Progression (growth of tumour): 5 people, 35.71%
  2. White Blood Cell Count Decreased: 4 people, 28.57%
  3. Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 4 people, 28.57%
  4. Hemiplegia (paralysis of one side of the body): 4 people, 28.57%
  5. Thrombocytopenia (decrease of platelets in blood): 4 people, 28.57%
  6. Dyspnea (difficult or laboured breathing): 3 people, 21.43%
  7. Venous Thrombosis (blood clot (thrombus) that forms within a vein): 3 people, 21.43%
  8. Anaplastic Astrocytoma (tumour of the glial (supportive) tissue of the brain): 2 people, 14.29%
  9. Mobility Decreased (ability to move is reduced): 2 people, 14.29%
  10. Speech Disorder: 1 person, 7.14%

What are the existing conditions these people have? *

  1. Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 3 people, 21.43%
  2. Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 2 people, 14.29%
  3. Diabetes: 2 people, 14.29%
  4. Anaplastic Astrocytoma (tumour of the glial (supportive) tissue of the brain): 2 people, 14.29%
  5. Pituitary Tumor: 1 person, 7.14%
  6. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 7.14%
  7. High Blood Cholesterol: 1 person, 7.14%
  8. Gastric Disorder (disease of stomach): 1 person, 7.14%
  9. Diabetes Insipidus (diabetes caused by a deficiency of the pituitary hormone vasopressin, which regulates kidney function): 1 person, 7.14%
  10. Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and have Neoplasm recurrence?

- Check whether Neoplasm recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Depakene:

Neoplasm recurrence treatments and more:

How severe was Neoplasm recurrence and when was it recovered:

Expand to all the drugs that have ingredients of valproic acid:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm recurrence:

Browse all the conditions that are associated with Neoplasm recurrence:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid (the active ingredients of Depakene) and Depakene (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.